At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 9, 2026 at 16:17 ET
ImageneBio reported Q3 2026 net loss of $15.6M ($0.91 per share), narrower than the $24.8M loss ($2.91 per share) in Q3 2025, driven by lower R&D and G&A expenses. The Phase 2b ADAPTIVE trial in atopic dermatitis continues as planned with topline data expected in Q4 2027, and a Phase 2 alopecia areata study is on track to start by year-end 2026. Cash of $126.6M provides runway into Q1 2028.
- Net loss of $15.6M for Q3 2026 vs $24.8M for Q3 2025
- Net loss per share $0.91 vs $2.91 in prior year period
- Cash, cash equivalents and marketable securities of $126.6M as of Sep 30, 2026
- R&D expenses $11.3M vs $15.2M in Q3 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access